建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
An European patent titled “USE OF FLAVONOID COMPOUND IN PREPARATION OF COMPOSITION FOR HEALING WOUND” has been granted.
Oneness Biotech Co., Ltd. receives a Hong Kong patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved as Class 1.1 natural new drug by National Medical Products Administration (NMPA) in China
The Company's 2023Q3 consolidated financial statements have been approved by the Board of Directors
Oneness has submitted medical device registration application of Bonvadis for wound care to the Thai Food and Drug Administration (Thai FDA) in Thailand.
The board of directors of the Company approved removal of the noncompete clause for managers.
The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.
Oneness has submitted medical device registration application for Bonvadis to the Egyptian Drug Authority (EDA).
Oneness announces the information about the investor's conference of 2023 Q3.
The board of directors of the Company approved removal of the noncompete clause for managers.
Oneness has submitted a 510(k) application to the U.S. FDA to expand the intended patient population and add multiple chronic wound indications for Bonvadis.
A Russian patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825 was granted.
The Company’s 2023 Q2 consolidated financial statements have been approved by the Board of Directors.
Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in South Africa.
Oneness was notified today that Bonvadis, the wound care topical cream has submitted a registration application to the Drug Regulatory Authority of Pakistan (DRAP).
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?